FDA Authorizes First AI Tech for Visualizing Coronary Inflammation in CT Scans

FDA Clears a Non-Invasive Test That Estimates a Heart Pressure Normally Measured with a Catheter

The FDA cleared CorVista's PCWP add-on, a non-invasive AI test estimating a heart pressure usually measured by catheter.

FDA authorizes first AI tech for visualizing coronary inflammation in CT scans

Cardiac imaging experts have been excited about this technology for quite some time. The belief is that it could help transform how clinicians evaluate cardiovascular risk.

Caristo Diagnostics' CaRi-Heart® Coronary Inflammation Technology Authorized by U.S. FDA

/PRNewswire/ -- Caristo Diagnostics, a global leader in AI technologies for cardiovascular disease, today announced that the U.S. Food and Drug Administration...

AI-powered coronary inflammation quantification tool given US FDA de novo authorisation

Caristo Diagnostics has announced that the US Food and Drug Administration (FDA) has granted de novo authorisation for its CaRi-Heart technology for the quantification of coronary inflammation from routine coronary CT angiography (CCTA). CaRi-Heart unmasks previously hidden inflammation and provides clinicians with actionable insights, enabling earlier intervention and personalised treatments for patients, the company says of the technology. Dev…

FDA Authorizes New Technology to Measure Heart Inflammation

The artificial intelligence platform analyzes routine coronary CT angiography to estimate patients’ 10-year cardiovascular risk. The US Food and Drug Administration (FDA) granted De Novo authorization to Caristo Diagnostics for its CaRi-Heart technology, which quantifies coronary inflammation from routine coronary CT angiography, according to a company press release. Coronary artery disease is the leading cause of death globally, and coronary in…

Caristo Diagnostics Receives FDA De Novo Authorization for CaRi-Heart AI Platform

What You Should Know Oxford spin-out Caristo Diagnostics has secured FDA De Novo authorization for CaRi-Heart®, making it the first and only technology authorized in the U.S. to quantify coronary inflammation from routine Coronary CT Angiography (CCTA).CaRi-Heart uses advanced AI to analyze inflammation-driven changes in the pericoronary adipose tissue, generating a Fat Attenuation Index Score (FAI-Score) and a 10-year personalized cardiovascula…